ZA200708775B - Substituted amide derivatives as protein kinase inhibitors - Google Patents
Substituted amide derivatives as protein kinase inhibitors Download PDFInfo
- Publication number
- ZA200708775B ZA200708775B ZA200708775A ZA200708775A ZA200708775B ZA 200708775 B ZA200708775 B ZA 200708775B ZA 200708775 A ZA200708775 A ZA 200708775A ZA 200708775 A ZA200708775 A ZA 200708775A ZA 200708775 B ZA200708775 B ZA 200708775B
- Authority
- ZA
- South Africa
- Prior art keywords
- optionally substituted
- phenyl
- alkyl
- methyl
- carboxamide
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title description 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title description 2
- 239000003909 protein kinase inhibitor Substances 0.000 title description 2
- -1 diastereomers Chemical class 0.000 claims description 268
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 258
- 125000000217 alkyl group Chemical group 0.000 claims description 192
- 125000001424 substituent group Chemical group 0.000 claims description 192
- 125000000623 heterocyclic group Chemical group 0.000 claims description 182
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 150
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 142
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 142
- 150000001875 compounds Chemical class 0.000 claims description 114
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 109
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 108
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 107
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 106
- 125000003118 aryl group Chemical group 0.000 claims description 66
- 125000004076 pyridyl group Chemical group 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 54
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 53
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 51
- 125000003003 spiro group Chemical group 0.000 claims description 50
- 125000001544 thienyl group Chemical group 0.000 claims description 50
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 48
- 150000002825 nitriles Chemical class 0.000 claims description 36
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 36
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims description 35
- 125000001246 bromo group Chemical group Br* 0.000 claims description 34
- 125000001153 fluoro group Chemical group F* 0.000 claims description 34
- 125000005843 halogen group Chemical group 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 19
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 125000001188 haloalkyl group Chemical class 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 12
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 10
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 206010027476 Metastases Diseases 0.000 claims description 6
- 150000001204 N-oxides Chemical class 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000009401 metastasis Effects 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 4
- 125000003418 alkyl amino alkoxy group Chemical group 0.000 claims description 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims description 4
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 125000004946 alkenylalkyl group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 2
- 125000005335 azido alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 9
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 9
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 claims 6
- 239000011570 nicotinamide Substances 0.000 claims 6
- 229960003966 nicotinamide Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 229940125697 hormonal agent Drugs 0.000 claims 2
- 239000000677 immunologic agent Substances 0.000 claims 2
- 229940124541 immunological agent Drugs 0.000 claims 2
- AVOHPVUAPGVLAY-UHFFFAOYSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-3-oxo-4-phenylmorpholine-2-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)OCCN1C1=CC=CC=C1 AVOHPVUAPGVLAY-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- NJQRAAHKQQPUIT-UHFFFAOYSA-N 1,2-dihydropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CNC1 NJQRAAHKQQPUIT-UHFFFAOYSA-N 0.000 claims 1
- HLYLVLPUVNOQHH-UHFFFAOYSA-N 1-(2-aminoethyl)-n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)N(CCN)N1C1=CC=CC=C1 HLYLVLPUVNOQHH-UHFFFAOYSA-N 0.000 claims 1
- KLWBNEIPBOZAOQ-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)N(C)N1C1=CC=CC=C1Cl KLWBNEIPBOZAOQ-UHFFFAOYSA-N 0.000 claims 1
- POEZAPIQLMNFDN-UHFFFAOYSA-N 1-(2-hydroxy-2-methylpropyl)-4-[7-(7-methoxyquinolin-4-yl)oxy-2,3-dihydro-1,4-benzoxazine-4-carbonyl]-5-methyl-2-phenylpyrazol-3-one Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=C1OCC2)=CC=C1N2C(=O)C(C1=O)=C(C)N(CC(C)(C)O)N1C1=CC=CC=C1 POEZAPIQLMNFDN-UHFFFAOYSA-N 0.000 claims 1
- IIZIRGJCJMFRDM-UHFFFAOYSA-N 1-(2-hydroxy-2-methylpropyl)-N-[5-(7-hydroxyquinolin-4-yl)oxypyridin-2-yl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound CC(O)(C)CN1C(C)=C(C(=O)NC=2N=CC(OC=3C4=CC=C(O)C=C4N=CC=3)=CC=2)C(=O)N1C1=CC=CC=C1 IIZIRGJCJMFRDM-UHFFFAOYSA-N 0.000 claims 1
- DSTCGXWRQMWOLU-UHFFFAOYSA-N 1-(2-hydroxy-2-methylpropyl)-n-[4-(7-methoxyquinolin-4-yl)sulfanylphenyl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1SC(C=C1)=CC=C1NC(=O)C(C1=O)=C(C)N(CC(C)(C)O)N1C1=CC=CC=C1 DSTCGXWRQMWOLU-UHFFFAOYSA-N 0.000 claims 1
- NXVHOYBQFPQTBF-UHFFFAOYSA-N 1-(3-amino-2-hydroxypropyl)-n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)N(CC(O)CN)N1C1=CC=CC=C1 NXVHOYBQFPQTBF-UHFFFAOYSA-N 0.000 claims 1
- BGLJTUOUNXPWKK-GOSISDBHSA-N 1-[(2r)-2-fluoropropyl]-n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=C(C)N(C[C@@H](C)F)N1C1=CC=CC=C1 BGLJTUOUNXPWKK-GOSISDBHSA-N 0.000 claims 1
- GODQNRDRRFCJJI-SANMLTNESA-N 1-[(2r)-2-hydroxy-3-methylbutyl]-n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=C(C)N(C[C@H](O)C(C)C)N1C1=CC=CC=C1 GODQNRDRRFCJJI-SANMLTNESA-N 0.000 claims 1
- PUVFWTQKDQUFCP-FQEVSTJZSA-N 1-[(2s)-2-(dimethylamino)propyl]-n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)N(C[C@H](C)N(C)C)N1C1=CC=CC=C1 PUVFWTQKDQUFCP-FQEVSTJZSA-N 0.000 claims 1
- NEOAGSZQQLXWTO-UHFFFAOYSA-N 1-benzyl-2-oxo-5-phenylpyridine-3-carboxamide Chemical compound O=C1C(C(=O)N)=CC(C=2C=CC=CC=2)=CN1CC1=CC=CC=C1 NEOAGSZQQLXWTO-UHFFFAOYSA-N 0.000 claims 1
- XUJAABYTWJFTEW-UHFFFAOYSA-N 1-benzyl-5-bromo-n-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-2-oxopyridine-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)C(C1=O)=CC(Br)=CN1CC1=CC=CC=C1 XUJAABYTWJFTEW-UHFFFAOYSA-N 0.000 claims 1
- DQOIOXHXYBCWOD-UHFFFAOYSA-N 1-benzyl-n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-2-oxo-5-pyrimidin-2-ylpyridine-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=CC(C=2N=CC=CN=2)=CN1CC1=CC=CC=C1 DQOIOXHXYBCWOD-UHFFFAOYSA-N 0.000 claims 1
- BSFMLWRRSOWTEQ-UHFFFAOYSA-N 1-benzyl-n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-4-(2-methoxyethylamino)-2-oxopyridine-3-carboxamide Chemical compound O=C1C(C(=O)NC=2N=CC(OC=3C4=CC(OC)=C(OC)C=C4N=CC=3)=CC=2)=C(NCCOC)C=CN1CC1=CC=CC=C1 BSFMLWRRSOWTEQ-UHFFFAOYSA-N 0.000 claims 1
- XOUIDBCXNCBWRA-UHFFFAOYSA-N 1-benzyl-n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=N1)=CC=C1NC(=O)C(C(N1C=2C=CC=CC=2)=O)=C(C)N1CC1=CC=CC=C1 XOUIDBCXNCBWRA-UHFFFAOYSA-N 0.000 claims 1
- ZVXKYWHJBYIYNI-UHFFFAOYSA-N 1h-pyrazole-4-carboxamide Chemical compound NC(=O)C=1C=NNC=1 ZVXKYWHJBYIYNI-UHFFFAOYSA-N 0.000 claims 1
- HPAXBNHGBRPUCO-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole-4-carboxamide Chemical compound NC(=O)C1=CNNC1 HPAXBNHGBRPUCO-UHFFFAOYSA-N 0.000 claims 1
- SLAASIAWHQRRKL-UHFFFAOYSA-N 2-phenyl-1-propyl-3h-pyrazole-4-carboxamide Chemical compound CCCN1C=C(C(N)=O)CN1C1=CC=CC=C1 SLAASIAWHQRRKL-UHFFFAOYSA-N 0.000 claims 1
- ONWIGSJBMCHKOV-UHFFFAOYSA-N 3-benzyl-n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-2-oxoimidazolidine-1-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)N(C1=O)CCN1CC1=CC=CC=C1 ONWIGSJBMCHKOV-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- NDKGNYXCMKDBKK-UHFFFAOYSA-N 3-oxo-2-phenyl-1h-pyrazole-4-carboxamide Chemical compound O=C1C(C(=O)N)=CNN1C1=CC=CC=C1 NDKGNYXCMKDBKK-UHFFFAOYSA-N 0.000 claims 1
- AKLARZWWYXICKZ-UHFFFAOYSA-N 4-(2-methoxyethylamino)-n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound O=C1C(C(=O)NC=2N=CC(OC=3C4=CC=C(OC)C=C4N=CC=3)=CC=2)=C(NCCOC)C=CN1C1=CC=CC=C1 AKLARZWWYXICKZ-UHFFFAOYSA-N 0.000 claims 1
- WEEMSRUOVNMUPV-UHFFFAOYSA-N 4-anilino-n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=N1)=CC=C1NC(=O)C(C(N(C=1C=CC=CC=1)C=C1)=O)=C1NC1=CC=CC=C1 WEEMSRUOVNMUPV-UHFFFAOYSA-N 0.000 claims 1
- RYQBKVFFHMNFTM-UHFFFAOYSA-N 5-(aminomethyl)-n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-1-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(CN)N(C)N1C1=CC=CC=C1 RYQBKVFFHMNFTM-UHFFFAOYSA-N 0.000 claims 1
- XHAJFXSLJHVISJ-UHFFFAOYSA-N 5-bromo-n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-1-(3-methylphenyl)-2-oxopyridine-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=CC(Br)=CN1C1=CC=CC(C)=C1 XHAJFXSLJHVISJ-UHFFFAOYSA-N 0.000 claims 1
- HBLJLTPJXZQZCK-UHFFFAOYSA-N 7-[2-fluoro-4-[[1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenylpyrazole-4-carbonyl]amino]phenoxy]-n-(2-methoxyethyl)thieno[3,2-b]pyridine-2-carboxamide Chemical compound C=12SC(C(=O)NCCOC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)N(CC(C)(C)O)N1C1=CC=CC=C1 HBLJLTPJXZQZCK-UHFFFAOYSA-N 0.000 claims 1
- AZIBPFHNLVDQOV-DKXQDJALSA-N CCCN1C(C)=C(C(=O)N[C@@H]2CC[C@@H](CC2)OC=2C3=CC=C(OC)C=C3N=CC=2)C(=O)N1C1=CC=CC=C1 Chemical compound CCCN1C(C)=C(C(=O)N[C@@H]2CC[C@@H](CC2)OC=2C3=CC=C(OC)C=C3N=CC=2)C(=O)N1C1=CC=CC=C1 AZIBPFHNLVDQOV-DKXQDJALSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 claims 1
- 229910019567 Re Re Inorganic materials 0.000 claims 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 claims 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000005518 carboxamido group Chemical group 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- QTSXUAWJQYJGBT-UHFFFAOYSA-N n-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-6-methyl-3-oxo-2-phenylpyridazine-4-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)C(C1=O)=CC(C)=NN1C1=CC=CC=C1 QTSXUAWJQYJGBT-UHFFFAOYSA-N 0.000 claims 1
- UKIOLJVLQRIDFS-UHFFFAOYSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-1-(2-hydroxy-2-methylbutyl)-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound CCC(C)(O)CN1C(C)=C(C(=O)NC=2C=C(F)C(OC=3C4=CC=C(OC)C=C4N=CC=3)=CC=2)C(=O)N1C1=CC=CC=C1 UKIOLJVLQRIDFS-UHFFFAOYSA-N 0.000 claims 1
- IJPGNMKSMUVFIK-UHFFFAOYSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-1-(2-hydroxy-3-morpholin-4-ylpropyl)-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C(N1C=2C=CC=CC=2)=O)=C(C)N1CC(O)CN1CCOCC1 IJPGNMKSMUVFIK-UHFFFAOYSA-N 0.000 claims 1
- ZGJSJVTYUHGLAA-UHFFFAOYSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-1-(4-fluorophenyl)-2,3-dimethyl-5-oxopyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)N(C)N1C1=CC=C(F)C=C1 ZGJSJVTYUHGLAA-UHFFFAOYSA-N 0.000 claims 1
- GYCPBMYHPVDKFK-JOCHJYFZSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-1-[(2r)-2-hydroxybutyl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound CC[C@@H](O)CN1C(C)=C(C(=O)NC=2C=C(F)C(OC=3C4=CC=C(OC)C=C4N=CC=3)=CC=2)C(=O)N1C1=CC=CC=C1 GYCPBMYHPVDKFK-JOCHJYFZSA-N 0.000 claims 1
- YMFWEIKNDBLHIR-HHHXNRCGSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-1-[(2s)-2-hydroxy-3-methylbutyl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)N(C[C@@H](O)C(C)C)N1C1=CC=CC=C1 YMFWEIKNDBLHIR-HHHXNRCGSA-N 0.000 claims 1
- PTDDHBPPQNYQQA-UHFFFAOYSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-1-[2-hydroxy-3-(methylamino)propyl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound CNCC(O)CN1C(C)=C(C(=O)NC=2C=C(F)C(OC=3C4=CC=C(OC)C=C4N=CC=3)=CC=2)C(=O)N1C1=CC=CC=C1 PTDDHBPPQNYQQA-UHFFFAOYSA-N 0.000 claims 1
- YRCSFWQLJFRPEI-UHFFFAOYSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-1-methyl-3-oxo-2-phenyl-5-(pyrrolidin-1-ylmethyl)pyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C(N(C=1C=CC=CC=1)N1C)=O)=C1CN1CCCC1 YRCSFWQLJFRPEI-UHFFFAOYSA-N 0.000 claims 1
- ZOQOSBOUUBEFAD-UHFFFAOYSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-5-methyl-1-(3-methyl-2-oxobutyl)-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)N(CC(=O)C(C)C)N1C1=CC=CC=C1 ZOQOSBOUUBEFAD-UHFFFAOYSA-N 0.000 claims 1
- GZMFYPWWSXGVTC-UHFFFAOYSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-5-methyl-3-oxo-1-(2-oxopropyl)-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)N(CC(C)=O)N1C1=CC=CC=C1 GZMFYPWWSXGVTC-UHFFFAOYSA-N 0.000 claims 1
- WYIOGRCUILYATA-UHFFFAOYSA-N n-[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]-5-methyl-3-oxo-1-(oxolan-2-ylmethyl)-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C(N1C=2C=CC=CC=2)=O)=C(C)N1CC1CCCO1 WYIOGRCUILYATA-UHFFFAOYSA-N 0.000 claims 1
- YOHXVPIILOONKY-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-2-(3-oxo-1h-isoindol-2-yl)acetamide Chemical compound C1C2=CC=CC=C2C(=O)N1CC(=O)NC(C=C1F)=CC=C1OC1=C(C=C(C(OC)=C2)OC)C2=NC=C1 YOHXVPIILOONKY-UHFFFAOYSA-N 0.000 claims 1
- AMZWENBKRDXBHQ-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-hydroxy-2-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1C2=CC=CC=C2C(=O)N1C(CO)C(=O)NC(C=C1F)=CC=C1OC1=C(C=C(C(OC)=C2)OC)C2=NC=C1 AMZWENBKRDXBHQ-UHFFFAOYSA-N 0.000 claims 1
- KNPGGOCAKBFOPN-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-5-(1-methylpyrazol-4-yl)-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=CC(C2=CN(C)N=C2)=CN1C1=CC=CC=C1 KNPGGOCAKBFOPN-UHFFFAOYSA-N 0.000 claims 1
- FPJDJIFCTZAITG-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-5-[(dimethylamino)methyl]-1-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(CN(C)C)N(C)N1C1=CC=CC=C1 FPJDJIFCTZAITG-UHFFFAOYSA-N 0.000 claims 1
- TUOUDQPJUIAYBY-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-5-methyl-3-oxo-1-(2-oxopropyl)-2-phenylpyrazole-4-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)N(CC(C)=O)N1C1=CC=CC=C1 TUOUDQPJUIAYBY-UHFFFAOYSA-N 0.000 claims 1
- GZAGUSLONPQDBT-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-5-methyl-3-oxo-2-phenyl-1h-pyrazole-4-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(C)NN1C1=CC=CC=C1 GZAGUSLONPQDBT-UHFFFAOYSA-N 0.000 claims 1
- VBFKCCNMXFXRBF-CQSZACIVSA-N n-[4-(6-aminopyrimidin-4-yl)oxy-3-fluorophenyl]-1-[(2r)-2-hydroxypropyl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound O=C1N(C=2C=CC=CC=2)N(C[C@H](O)C)C(C)=C1C(=O)NC(C=C1F)=CC=C1OC1=CC(N)=NC=N1 VBFKCCNMXFXRBF-CQSZACIVSA-N 0.000 claims 1
- VAPLAAHRJUSDQJ-UHFFFAOYSA-N n-[4-[4-[(1,5-dimethyl-3-oxo-2-phenylpyrazole-4-carbonyl)amino]-2-fluorophenoxy]pyridin-2-yl]morpholine-4-carboxamide Chemical compound O=C1N(C=2C=CC=CC=2)N(C)C(C)=C1C(=O)NC(C=C1F)=CC=C1OC(C=1)=CC=NC=1NC(=O)N1CCOCC1 VAPLAAHRJUSDQJ-UHFFFAOYSA-N 0.000 claims 1
- UVBUNGUGIALSIJ-HSZRJFAPSA-N n-[4-[6-[[(3r)-3-(dimethylamino)pyrrolidine-1-carbonyl]amino]pyrimidin-4-yl]oxy-3-fluorophenyl]-3-methyl-5-oxo-1-phenyl-2-propylpyrazole-4-carboxamide Chemical compound O=C1N(C=2C=CC=CC=2)N(CCC)C(C)=C1C(=O)NC(C=C1F)=CC=C1OC(N=CN=1)=CC=1NC(=O)N1CC[C@@H](N(C)C)C1 UVBUNGUGIALSIJ-HSZRJFAPSA-N 0.000 claims 1
- KVPRSEQEHWCFIY-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-3-methyl-5-oxo-1-phenyl-2-propylpyrazole-4-carboxamide Chemical compound CCCN1C(C)=C(C(=O)NC=2N=CC(OC=3C4=CC(OC)=C(OC)C=C4N=CC=3)=CC=2)C(=O)N1C1=CC=CC=C1 KVPRSEQEHWCFIY-UHFFFAOYSA-N 0.000 claims 1
- WULRGSKYDLRNLL-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-4-(dimethylamino)-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=C(N(C)C)C=CN1C1=CC=CC=C1 WULRGSKYDLRNLL-UHFFFAOYSA-N 0.000 claims 1
- DSTDNBAORRODRL-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-4-(methylamino)-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound O=C1C(C(=O)NC=2N=CC(OC=3C4=CC(OC)=C(OC)C=C4N=CC=3)=CC=2)=C(NC)C=CN1C1=CC=CC=C1 DSTDNBAORRODRL-UHFFFAOYSA-N 0.000 claims 1
- QFBIGXSOTHTHGD-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-4-(oxan-4-ylamino)-2-oxo-1-phenylpyridine-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=N1)=CC=C1NC(=O)C(C(N(C=1C=CC=CC=1)C=C1)=O)=C1NC1CCOCC1 QFBIGXSOTHTHGD-UHFFFAOYSA-N 0.000 claims 1
- GODJFMYOWZKKJA-UHFFFAOYSA-N n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-1-methyl-3-oxo-2-phenyl-5-(pyrrolidin-1-ylmethyl)pyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=N1)=CC=C1NC(=O)C(C(N(C=1C=CC=CC=1)N1C)=O)=C1CN1CCCC1 GODJFMYOWZKKJA-UHFFFAOYSA-N 0.000 claims 1
- ISRQETGPAFAXMC-UHFFFAOYSA-N n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-1-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CN(C)N1C1=CC=CC=C1 ISRQETGPAFAXMC-UHFFFAOYSA-N 0.000 claims 1
- BUKHWHCWUHMPKB-UHFFFAOYSA-N n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-1-methyl-5-(5-methyl-1,2-oxazol-3-yl)-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=N1)=CC=C1NC(=O)C(C(N(C=1C=CC=CC=1)N1C)=O)=C1C=1C=C(C)ON=1 BUKHWHCWUHMPKB-UHFFFAOYSA-N 0.000 claims 1
- LUAWSFFQLRPDPM-UHFFFAOYSA-N n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-3-methyl-5-oxo-1-phenyl-2-propylpyrazole-4-carboxamide Chemical compound CCCN1C(C)=C(C(=O)NC=2N=CC(OC=3C4=CC=C(OC)C=C4N=CC=3)=CC=2)C(=O)N1C1=CC=CC=C1 LUAWSFFQLRPDPM-UHFFFAOYSA-N 0.000 claims 1
- GHKSBYMPPJLVOA-UHFFFAOYSA-N n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-5-methyl-1-(2-methylpropyl)-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=C(C)N(CC(C)C)N1C1=CC=CC=C1 GHKSBYMPPJLVOA-UHFFFAOYSA-N 0.000 claims 1
- RSVBIUVWFKMUOU-UHFFFAOYSA-N n-[6-[2-fluoro-4-[(3-methyl-5-oxo-1-phenyl-2-propylpyrazole-4-carbonyl)amino]phenoxy]pyrimidin-4-yl]piperidine-1-carboxamide Chemical compound O=C1N(C=2C=CC=CC=2)N(CCC)C(C)=C1C(=O)NC(C=C1F)=CC=C1OC(N=CN=1)=CC=1NC(=O)N1CCCCC1 RSVBIUVWFKMUOU-UHFFFAOYSA-N 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 claims 1
- SYZOGIWQIHJHKJ-UHFFFAOYSA-N tert-butyl n-[[4-[[3-fluoro-4-(7-methoxyquinolin-4-yl)oxyphenyl]carbamoyl]-2-methyl-5-oxo-1-phenylpyrazol-3-yl]methyl]carbamate Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=C(CNC(=O)OC(C)(C)C)N(C)N1C1=CC=CC=C1 SYZOGIWQIHJHKJ-UHFFFAOYSA-N 0.000 claims 1
- ZBWCOZDGHJCGSC-UHFFFAOYSA-N thieno[3,2-b]pyridine-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=N1 ZBWCOZDGHJCGSC-UHFFFAOYSA-N 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 18
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 16
- 230000033115 angiogenesis Effects 0.000 description 13
- 230000012010 growth Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 230000006444 vascular growth Effects 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 3
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 150000003248 quinolines Chemical class 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000023819 chronic asthma Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 2
- IDPWXVBDDIYDKT-UHFFFAOYSA-N 2-phenoxyquinoline Chemical class C=1C=C2C=CC=CC2=NC=1OC1=CC=CC=C1 IDPWXVBDDIYDKT-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 102100023263 Cyclin-dependent kinase 10 Human genes 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 101150036586 FES gene Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000908138 Homo sapiens Cyclin-dependent kinase 10 Proteins 0.000 description 1
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150054473 PTK2 gene Proteins 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 108010082093 Placenta Growth Factor Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000027746 artery morphogenesis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000010046 negative regulation of endothelial cell proliferation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000030795 positive regulation of cellular component movement Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical class NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- YMNAJWHTELQUJU-UHFFFAOYSA-N quinoline-6-carboxamide Chemical class N1=CC=CC2=CC(C(=O)N)=CC=C21 YMNAJWHTELQUJU-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67580505P | 2005-04-27 | 2005-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200708775B true ZA200708775B (en) | 2008-06-25 |
Family
ID=36617399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200708775A ZA200708775B (en) | 2005-04-27 | 2007-10-15 | Substituted amide derivatives as protein kinase inhibitors |
Country Status (34)
Country | Link |
---|---|
US (3) | US7858623B2 (es) |
EP (1) | EP1881976B1 (es) |
JP (1) | JP5463033B2 (es) |
KR (1) | KR20080004617A (es) |
CN (1) | CN101248059A (es) |
AR (1) | AR054262A1 (es) |
AU (1) | AU2006239216B2 (es) |
BR (1) | BRPI0608097A2 (es) |
CA (1) | CA2605680C (es) |
CR (1) | CR9475A (es) |
CY (1) | CY1113324T1 (es) |
DK (1) | DK1881976T3 (es) |
EA (1) | EA013231B1 (es) |
ES (1) | ES2396219T3 (es) |
GT (1) | GT200600181A (es) |
HK (1) | HK1116161A1 (es) |
HN (1) | HN2006016313A (es) |
HR (1) | HRP20121069T1 (es) |
IL (1) | IL186526A (es) |
JO (1) | JO2787B1 (es) |
MX (1) | MX2007013216A (es) |
MY (1) | MY177111A (es) |
NO (1) | NO20076093L (es) |
NZ (1) | NZ562595A (es) |
PE (1) | PE20061436A1 (es) |
PL (1) | PL1881976T3 (es) |
PT (1) | PT1881976E (es) |
RS (1) | RS52596B (es) |
SI (1) | SI1881976T1 (es) |
TW (1) | TWI378094B (es) |
UA (1) | UA93375C2 (es) |
UY (1) | UY29503A1 (es) |
WO (1) | WO2006116713A1 (es) |
ZA (1) | ZA200708775B (es) |
Families Citing this family (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
EA011402B1 (ru) * | 2004-01-23 | 2009-02-27 | Эмджен Инк. | Азотсодержащие гетероциклические производные и их фармацевтические применения |
AU2005266803B2 (en) | 2004-07-30 | 2011-10-27 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
PL1928454T3 (pl) | 2005-05-10 | 2015-03-31 | Intermune Inc | Pochodne pirydonu do modulowania układu kinazy białkowej aktywowanego stresem |
BRPI0610382A2 (pt) | 2005-05-20 | 2010-06-15 | Methylgene Inc | inibidores de sinalização de receptor de vegf e receptor de hgf |
WO2008041053A2 (en) * | 2005-05-20 | 2008-04-10 | Methylgene, Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
CA2624826A1 (en) * | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
WO2008063202A2 (en) | 2006-01-30 | 2008-05-29 | Array Biopharma Inc. | Heterobicyclic thiophene compounds for the treatment of cancer |
MX2008011220A (es) | 2006-03-07 | 2008-09-11 | Array Biopharma Inc | Compuestos de pirazol heterobiciclicos y metodos de uso. |
ES2643469T3 (es) | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos |
TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
WO2008048375A1 (en) * | 2006-05-19 | 2008-04-24 | Bayer Healthcare Ag | Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders |
US20080004273A1 (en) * | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
CA2655128A1 (en) * | 2006-06-08 | 2007-12-21 | Array Biopharma Inc. | Quinoline compounds and methods of use |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US8778977B2 (en) | 2006-06-30 | 2014-07-15 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl PDK1 inhibitors |
US7851489B2 (en) | 2006-11-08 | 2010-12-14 | Bristol-Myers Squibb Company | Pyridinone compounds |
WO2008079292A1 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
ES2392156T3 (es) * | 2006-12-20 | 2012-12-05 | Amgen Inc. | Heterociclos sustituidos y métodos de uso |
CA2672438A1 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
AU2008219166B2 (en) * | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
BRPI0816064B8 (pt) * | 2007-08-29 | 2021-05-25 | Methylgene Inc | composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica |
EP2183255A4 (en) | 2007-08-29 | 2011-06-15 | Methylgene Inc | METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF CONDENSED HETEROCYCLIC KINASE INHIBITORS |
WO2009054544A1 (en) * | 2007-10-26 | 2009-04-30 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists for parkinson's disease and movement disorders |
EP2220078B1 (en) * | 2007-10-29 | 2013-05-22 | Amgen, Inc | Benzomorpholine derivatives and methods of use |
WO2009061271A1 (en) | 2007-11-06 | 2009-05-14 | Astrazeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
WO2009094427A1 (en) | 2008-01-23 | 2009-07-30 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
EP2235002B1 (en) | 2008-01-23 | 2012-11-21 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
AU2009221583B2 (en) * | 2008-03-05 | 2013-06-20 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
MX2010012290A (es) * | 2008-05-14 | 2011-02-21 | Amgen Inc | Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. |
CA3034994A1 (en) | 2008-06-03 | 2009-12-10 | Intermune, Inc. | Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders |
TWI365185B (en) | 2008-07-24 | 2012-06-01 | Lilly Co Eli | Amidophenoxyindazoles useful as inhibitors of c-met |
NZ605292A (en) | 2008-08-20 | 2014-06-27 | Zoetis Services Llc | Pyrrolo[2,3-d]pyrimidine compounds |
CA2738314C (en) * | 2008-09-23 | 2017-01-10 | Georgetown University | 1,2-benzisothiazolinone and isoindolinone derivatives |
MX2011003363A (es) * | 2008-10-01 | 2011-04-27 | Ludwig Inst Cancer Res | Metodos para el tratamiento de cancer. |
RU2011119478A (ru) * | 2008-10-14 | 2012-11-27 | Нин Си | Соединения и способы применения |
KR100961410B1 (ko) * | 2008-10-14 | 2010-06-09 | (주)네오팜 | 단백질 키나제 억제제로서 헤테로사이클릭 화합물 |
EP2373636A4 (en) * | 2008-12-05 | 2012-10-17 | Merck Sharp & Dohme | INHIBITORS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1) |
US8691866B2 (en) * | 2008-12-10 | 2014-04-08 | The General Hospital Corporation | HIF inhibitors and use thereof |
AR074830A1 (es) | 2008-12-19 | 2011-02-16 | Cephalon Inc | Pirrolotriazinas como inhibidores de alk y jak2 |
AU2010271105C1 (en) | 2009-01-12 | 2014-08-21 | Aerpio Therapeutics, Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
JP5583751B2 (ja) | 2009-03-21 | 2014-09-03 | クイ ニング | アミノエステル誘導体、その塩、及び使用方法 |
US8367836B2 (en) * | 2009-04-27 | 2013-02-05 | Elan Pharmaceuticals, Inc. | Pyridinone antagonists of alpha-4 integrins |
EP2473513B1 (en) | 2009-09-03 | 2019-06-05 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
CN102574789B (zh) * | 2009-09-21 | 2014-12-10 | 凯莫森特里克斯股份有限公司 | 吡咯烷酮甲酰胺衍生物作为趋化素-r(chemr23)调节剂 |
CA2773618A1 (en) | 2009-10-02 | 2011-04-07 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
WO2011051958A1 (en) | 2009-10-30 | 2011-05-05 | E.I. Du Pont De Nemours And Company | Fungicidal pyrazolones |
EP2521723A1 (en) | 2010-01-04 | 2012-11-14 | Enantia, S.L. | Process for the preparation of rivaroxaban and intermediates thereof |
CN102212062B (zh) * | 2010-04-02 | 2015-04-29 | 广东东阳光药业有限公司 | 氨基酯类衍生物及其盐和使用方法 |
CN103025740B (zh) * | 2010-04-16 | 2015-07-01 | 梅特希尔基因公司 | 蛋白酪氨酸激酶活性的抑制剂及其治疗眼科疾病的用途 |
US8569319B2 (en) | 2010-04-29 | 2013-10-29 | Deciphera Pharmaceuticals, LLS | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
ES2715611T3 (es) | 2010-05-17 | 2019-06-05 | Incozen Therapeutics Pvt Ltd | Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas |
WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
JP5789259B2 (ja) * | 2010-07-16 | 2015-10-07 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
EP2423208A1 (en) * | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
US8895245B2 (en) | 2010-09-10 | 2014-11-25 | Epizyme, Inc. | Inhibitors of human EZH2 and methods of use thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
US20140057908A1 (en) | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
RU2568258C2 (ru) | 2011-02-28 | 2015-11-20 | Саншайн Лейк Фарма Ко., Лтд | Замещенные соединения хинолина и способы их использования |
SG192769A1 (en) | 2011-03-04 | 2013-09-30 | Glaxosmithkline Ip No 2 Ltd | Amino-quinolines as kinase inhibitors |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
JP6001072B2 (ja) * | 2011-08-10 | 2016-10-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | ピリド−ピリミジン誘導体 |
AU2012296543B2 (en) | 2011-08-16 | 2016-08-11 | Georgetown University | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
ES2702495T3 (es) | 2011-08-30 | 2019-03-01 | Astex Pharmaceuticals Inc | Formulaciones de derivados de decitabina |
WO2013056233A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
CN104302292A (zh) * | 2011-11-22 | 2015-01-21 | 德西费拉制药有限责任公司 | 表现出抗癌和抗增殖活性的吡啶酮酰胺以及类似物 |
CN102643268B (zh) * | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | 喹啉类及噌啉类化合物及其应用 |
CN103319468B (zh) * | 2012-03-21 | 2016-07-13 | 广东东阳光药业有限公司 | 取代的螺双环化合物及其使用方法和用途 |
EP2831073B1 (en) | 2012-03-30 | 2020-12-09 | Rhizen Pharmaceuticals S.A. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases |
EP4190777A1 (en) | 2012-04-13 | 2023-06-07 | Epizyme, Inc. | Hbr salt form for ezh2 inhibition |
CN103420986A (zh) * | 2012-05-18 | 2013-12-04 | 广东东阳光药业有限公司 | 取代的喹啉化合物及其使用方法和用途 |
AU2013283543B2 (en) * | 2012-06-26 | 2017-11-02 | Bayer Pharma Aktiengesellschaft | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products |
TWI520962B (zh) * | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
CN104507930B (zh) * | 2012-06-29 | 2017-10-10 | 贝达药业股份有限公司 | 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物 |
CN103539780A (zh) * | 2012-07-16 | 2014-01-29 | 广东东阳光药业有限公司 | 取代的吡唑酮化合物及其使用方法和用途 |
US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
WO2014022117A1 (en) * | 2012-07-28 | 2014-02-06 | Calitor Sciences, Llc | Substituted pyrazolone compounds and methods of use |
TWI565702B (zh) * | 2012-08-03 | 2017-01-11 | 習寧 | 取代的吡唑酮化合物及其使用方法 |
KR101350006B1 (ko) * | 2012-09-06 | 2014-02-13 | 씨제이제일제당 (주) | 피리돈 유도체를 포함하는 단백질 키나제 억제제 |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CA2888021A1 (en) | 2012-10-15 | 2014-04-24 | Epizyme, Inc. | Substituted n-((2-oxo-1,2-dihydropyridin-3-yl)-methyl)-benzamide compounds and their use in the treatment of ezh2-mediated disorders |
US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
BR112015019624A2 (pt) | 2013-02-21 | 2017-07-18 | Glaxosmithkline Ip Dev Ltd | quinazolinas como inibidores de quinase |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
NO3003315T3 (es) | 2013-06-06 | 2018-06-16 | ||
TWI649308B (zh) * | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
MY179802A (en) | 2013-10-16 | 2020-11-16 | Eisai R&D Man Co Ltd | Hydrochloride salt form for ezh2 inhibition |
WO2015066482A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
CN104974162B (zh) * | 2014-04-09 | 2018-09-14 | 广东东阳光药业有限公司 | 双环吡唑酮化合物及其使用方法和用途 |
EP3134088B1 (en) * | 2014-04-22 | 2019-04-10 | Calitor Sciences, LLC | Bicylcic pyrazolone compounds and methods of use |
US10208034B2 (en) | 2014-12-25 | 2019-02-19 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
DK3286177T3 (da) | 2015-04-14 | 2020-06-08 | Qurient Co Ltd | Quinolinderivater som tam rtk-inhibitorer |
CN106279147A (zh) | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
BR112018000054A2 (pt) | 2015-07-02 | 2018-09-04 | Otsuka Pharmaceutical Co., Ltd. | composições farmacêuticas liofilizadas |
CA2990752C (en) * | 2015-07-20 | 2020-03-10 | Betta Pharmaceuticals Co., Ltd | Crystalline form of fused pyridine derivative's maleate and uses thereof |
CN106632253B (zh) * | 2015-11-02 | 2019-03-22 | 广东东阳光药业有限公司 | 一种取代的喹啉化合物的晶型及其药物组合物和用途 |
CN106632254B (zh) * | 2015-11-02 | 2019-03-01 | 广东东阳光药业有限公司 | 一种取代的喹啉化合物的晶型及其药物组合物和用途 |
JP6905662B2 (ja) * | 2015-11-14 | 2021-07-21 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 置換キノリン化合物の結晶形およびその医薬組成物 |
EP3373932B1 (en) * | 2015-11-14 | 2022-03-30 | Sunshine Lake Pharma Co., Ltd. | Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof |
WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
CN107286140A (zh) * | 2016-04-12 | 2017-10-24 | 上海医药工业研究院 | 取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用 |
WO2017198196A1 (zh) * | 2016-05-18 | 2017-11-23 | 王子厚 | 具有抗肿瘤活性的喹啉衍生物 |
EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
KR20190051010A (ko) | 2016-09-08 | 2019-05-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정형 및 그의 용도 |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN110099898B (zh) | 2016-10-24 | 2023-07-25 | 优曼尼蒂治疗公司 | 化合物及其用途 |
HRP20220636T1 (hr) | 2016-12-09 | 2022-07-22 | Denali Therapeutics Inc. | Spojevi korisni kao inhibitori ripk1 |
MX2019008787A (es) | 2017-01-26 | 2019-09-11 | Ono Pharmaceutical Co | Sal de etano-sulfonato del derivado de quinolina. |
KR102603153B1 (ko) | 2017-04-27 | 2023-11-15 | 아스트라제네카 아베 | C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도 |
WO2019016071A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES |
KR20200035438A (ko) | 2017-08-03 | 2020-04-03 | 오쓰까 세이야꾸 가부시키가이샤 | 약물 화합물 및 이의 정제 방법 |
WO2019048988A1 (en) | 2017-09-08 | 2019-03-14 | Pi Industries Ltd. | NOVEL FUNGICIDE HETEROCYCLIC COMPOUNDS |
US20200281202A1 (en) | 2017-09-08 | 2020-09-10 | Pi Industries Ltd. | Novel fungicidal heterocyclic compounds |
US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
CN110041316B (zh) * | 2018-01-17 | 2022-04-19 | 药捷安康(南京)科技股份有限公司 | Tam家族激酶/和csf1r激酶抑制剂及其用途 |
CA3072169C (en) | 2018-03-08 | 2022-04-19 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
CA3094527A1 (en) * | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
CN110372666B (zh) * | 2018-04-13 | 2022-11-08 | 华东理工大学 | 喹唑啉类化合物作为egfr三突变抑制剂及其应用 |
CN110511218A (zh) * | 2018-05-21 | 2019-11-29 | 中国科学院上海药物研究所 | 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途 |
JP7090958B2 (ja) * | 2018-06-01 | 2022-06-27 | アドレイ・ノーティ・バイオファーマ・カンパニー・リミテッド | 高活性csf1r阻害薬化合物 |
CN108727386A (zh) * | 2018-07-16 | 2018-11-02 | 广州医科大学 | 一种吡唑并嘧啶类化合物及其制备方法和用途 |
EP3842425B1 (en) * | 2018-08-24 | 2024-05-22 | TransThera Sciences (Nanjing), Inc. | Novel quinoline derivative inhibitor |
EP3894406A1 (en) | 2018-12-11 | 2021-10-20 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
CN111303024B (zh) * | 2018-12-12 | 2023-03-28 | 安徽中科拓苒药物科学研究有限公司 | 一种喹啉结构的pan-KIT激酶抑制剂及其用途 |
WO2021020362A1 (ja) * | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | 複素環化合物 |
WO2021026100A1 (en) * | 2019-08-02 | 2021-02-11 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
WO2021023888A1 (en) * | 2019-08-08 | 2021-02-11 | B.C.I. Pharma | Isoquinoline derivatives as protein kinase inhibitors |
KR20220059386A (ko) | 2019-09-06 | 2022-05-10 | 웰마커바이오 주식회사 | 바이오마커 기반 치료용 조성물 |
CN112625026B (zh) * | 2019-09-24 | 2022-09-09 | 药捷安康(南京)科技股份有限公司 | Tam家族激酶抑制剂的喹啉衍生物 |
CN113121429B (zh) * | 2020-01-15 | 2024-04-26 | 鲁南制药集团股份有限公司 | 一种c-Met激酶抑制剂及其制备方法和应用 |
WO2021173591A1 (en) * | 2020-02-24 | 2021-09-02 | Exelixis, Inc. | Compounds and methods of use |
CN111440174B (zh) * | 2020-04-02 | 2021-07-09 | 广州医科大学 | 一种吡啶酰胺类化合物及其制备方法与应用 |
WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
US20240174683A1 (en) | 2021-02-05 | 2024-05-30 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
TWI822140B (zh) * | 2021-06-24 | 2023-11-11 | 南韓商Lg化學股份有限公司 | 作為ron抑制劑之新穎吡啶衍生物化合物 |
CN113999205B (zh) * | 2021-12-13 | 2023-09-15 | 辽宁大学 | 含三氮唑酮酰胺和咪唑酰胺结构的吡啶类化合物及其应用 |
CN117362275A (zh) * | 2022-06-29 | 2024-01-09 | 广州百霆医药科技有限公司 | 一种酪氨酸蛋白激酶抑制剂及其用途 |
CN116283920B (zh) * | 2023-03-31 | 2024-04-16 | 贵州医科大学 | 2,4-二取代吡啶类化合物及其应用 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755332A (en) | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
DE2948434A1 (de) * | 1979-12-01 | 1981-06-11 | Hoechst Ag, 6000 Frankfurt | 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung |
JPS63145272A (ja) | 1986-12-09 | 1988-06-17 | Morishita Seiyaku Kk | 4,5−ジヒドロ−6−(4−置換フエニル)−3(2h)−ピリダジノン誘導体 |
US4916135A (en) | 1989-05-08 | 1990-04-10 | Hoechst Roussel Pharmaceuticals Inc. | N-heteroaryl-4-quinolinamines |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
JPH08193070A (ja) * | 1995-01-11 | 1996-07-30 | Mitsubishi Chem Corp | 2−イミダゾリジノン誘導体及びそれを有効成分とする除草剤、並びにその製造中間体 |
WO1996023774A1 (fr) | 1995-01-31 | 1996-08-08 | Zenyaku Kogyo Kabushiki Kaisha | Derives de thioquinoline |
GB9505702D0 (en) | 1995-03-21 | 1995-05-10 | Agrevo Uk Ltd | Fungicidal compounds |
GB9505651D0 (en) | 1995-03-21 | 1995-05-10 | Agrevo Uk Ltd | AgrEvo UK Limited |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
JP4009681B2 (ja) | 1995-11-07 | 2007-11-21 | キリンファーマ株式会社 | 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物 |
AU7292096A (en) | 1995-11-14 | 1997-06-05 | Pharmacia & Upjohn S.P.A. | Aryl and heteroaryl purine compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
DE19614718A1 (de) | 1996-04-15 | 1997-10-16 | Hoechst Schering Agrevo Gmbh | Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel |
JP4495257B2 (ja) | 1997-02-19 | 2010-06-30 | バーレツクス ラボラトリーズ インコーポレーテツド | Nos抑制剤としてのn−複素環誘導体 |
JP4194678B2 (ja) | 1997-11-28 | 2008-12-10 | キリンファーマ株式会社 | キノリン誘導体およびそれを含む医薬組成物 |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
WO1999054309A1 (en) | 1998-04-23 | 1999-10-28 | Takeda Chemical Industries, Ltd. | Naphthalene derivatives, their production and use |
IL139641A0 (en) | 1998-05-28 | 2002-02-10 | Parker Hughes Inst | Quinazolines for treating brain tumor |
IL141434A0 (en) | 1998-08-21 | 2002-03-10 | Parker Hughes Inst | Quinazoline derivatives |
PL204856B1 (pl) | 1999-01-22 | 2010-02-26 | Kirin Pharma Kk | Pochodne chinoliny lub chinazoliny, jej zastosowanie i kompozycja farmaceutyczna |
ES2351699T3 (es) | 1999-02-10 | 2011-02-09 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de la angiogénesis e intermedios de los mismos. |
GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
EP1183254B1 (en) | 1999-04-12 | 2005-01-12 | Aventis Pharma Limited | Substituted bicyclic heteroaryl compounds as integrin antagonists |
JP2003509497A (ja) | 1999-09-21 | 2003-03-11 | アストラゼネカ アクチボラグ | キナゾリン化合物とそれらを含有する医薬組成物 |
EP1263756B1 (en) | 2000-03-17 | 2004-02-25 | Bristol-Myers Squibb Pharma Company | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
JP2003528072A (ja) | 2000-03-17 | 2003-09-24 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | マトリックスメタロプロテアーゼおよびTNF−αの阻害剤としての環状β−アミノ酸誘導体 |
AU2001268545A1 (en) | 2000-06-21 | 2002-01-08 | Alexion Pharmaceuticals, Inc. | Libraries displaying human antibody fragments with hybrid complementarity determining regions |
MXPA03002299A (es) | 2000-09-15 | 2003-06-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de proteina cinasa. |
US6849625B2 (en) | 2000-10-13 | 2005-02-01 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
KR100589032B1 (ko) | 2000-10-20 | 2006-06-14 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
JP4343534B2 (ja) | 2001-03-02 | 2009-10-14 | ゲーペーツェー バイオテック アクチェンゲゼルシャフト | 3ハイブリッド・アッセイ・システム |
DE60211317T2 (de) | 2001-03-23 | 2007-04-12 | Bayer Corp. | Rho-kinase inhibitoren |
EP1392306B1 (en) | 2001-06-06 | 2008-01-16 | Aventis Pharma Limited | Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases |
WO2003000660A1 (en) | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
WO2002000004A2 (en) | 2001-07-05 | 2002-01-03 | Telefonaktiebolaget Lm Ericsson (Publ) | Detrimental latch-up avoidans in digital circuits |
SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
RU2004116911A (ru) | 2001-11-03 | 2005-11-10 | Астразенека Аб (Se) | Производные хиназолина в качестве противоопухолевых средств |
MXPA04007459A (es) | 2002-02-01 | 2005-09-08 | Astrazeneca Ab | Compuestos de quinazolina. |
US6818772B2 (en) * | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
DE60329910D1 (de) | 2002-03-29 | 2009-12-17 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
KR100942073B1 (ko) | 2002-08-23 | 2010-02-12 | 기린 홀딩스 가부시키가이샤 | TGF β 저해 활성을 갖는 화합물 및 그것을 포함하여 이루어지는 의약 조성물 |
AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
US7495016B2 (en) | 2002-10-21 | 2009-02-24 | Irm Llc | Pyrrolidones with anti-HIV activity |
TW200418466A (en) | 2002-11-06 | 2004-10-01 | Smithkline Beecham Corp | Chemical compounds |
TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
GB0226724D0 (en) | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
AU2004218456A1 (en) | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists. |
AU2004221812B2 (en) | 2003-03-19 | 2010-02-18 | Exelixis Inc. | Tie-2 modulators and methods of use |
US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
GB0310401D0 (en) | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
AU2004255566B2 (en) | 2003-07-07 | 2010-07-08 | Merk Patent Gmbh | Malonamide derivatives |
EP1660503A1 (en) | 2003-08-29 | 2006-05-31 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
ES2371383T3 (es) | 2003-09-26 | 2011-12-30 | Exelixis, Inc. | N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer. |
CA2542329A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
EA011402B1 (ru) | 2004-01-23 | 2009-02-27 | Эмджен Инк. | Азотсодержащие гетероциклические производные и их фармацевтические применения |
AU2005207946A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
JPWO2005080377A1 (ja) | 2004-02-20 | 2007-10-25 | キリンホールディングス株式会社 | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
US7523317B2 (en) | 2004-04-29 | 2009-04-21 | International Business Machines Corporation | Computer grid access management system |
US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
-
2006
- 2006-04-25 JO JO2006118A patent/JO2787B1/en active
- 2006-04-26 US US11/412,302 patent/US7858623B2/en active Active
- 2006-04-26 MY MYPI20061913A patent/MY177111A/en unknown
- 2006-04-26 TW TW095114947A patent/TWI378094B/zh not_active IP Right Cessation
- 2006-04-26 AR AR20060101671A patent/AR054262A1/es not_active Application Discontinuation
- 2006-04-27 PL PL06751834T patent/PL1881976T3/pl unknown
- 2006-04-27 MX MX2007013216A patent/MX2007013216A/es active IP Right Grant
- 2006-04-27 NZ NZ562595A patent/NZ562595A/en not_active IP Right Cessation
- 2006-04-27 GT GT200600181A patent/GT200600181A/es unknown
- 2006-04-27 JP JP2008509191A patent/JP5463033B2/ja not_active Expired - Fee Related
- 2006-04-27 PE PE2006000442A patent/PE20061436A1/es not_active Application Discontinuation
- 2006-04-27 SI SI200631479T patent/SI1881976T1/sl unknown
- 2006-04-27 DK DK06751834.0T patent/DK1881976T3/da active
- 2006-04-27 RS RS20120566A patent/RS52596B/en unknown
- 2006-04-27 UA UAA200713130A patent/UA93375C2/ru unknown
- 2006-04-27 BR BRPI0608097-9A patent/BRPI0608097A2/pt not_active IP Right Cessation
- 2006-04-27 PT PT06751834T patent/PT1881976E/pt unknown
- 2006-04-27 HN HN2006016313A patent/HN2006016313A/es unknown
- 2006-04-27 WO PCT/US2006/016344 patent/WO2006116713A1/en active Application Filing
- 2006-04-27 KR KR1020077027041A patent/KR20080004617A/ko active IP Right Grant
- 2006-04-27 UY UY29503A patent/UY29503A1/es not_active Application Discontinuation
- 2006-04-27 EP EP06751834A patent/EP1881976B1/en active Active
- 2006-04-27 ES ES06751834T patent/ES2396219T3/es active Active
- 2006-04-27 CN CNA2006800231692A patent/CN101248059A/zh active Pending
- 2006-04-27 AU AU2006239216A patent/AU2006239216B2/en not_active Ceased
- 2006-04-27 EA EA200702339A patent/EA013231B1/ru not_active IP Right Cessation
- 2006-04-27 CA CA2605680A patent/CA2605680C/en not_active Expired - Fee Related
-
2007
- 2007-10-09 IL IL186526A patent/IL186526A/en not_active IP Right Cessation
- 2007-10-15 ZA ZA200708775A patent/ZA200708775B/en unknown
- 2007-10-26 CR CR9475A patent/CR9475A/es unknown
- 2007-11-26 NO NO20076093A patent/NO20076093L/no not_active Application Discontinuation
-
2008
- 2008-04-07 HK HK08103876.5A patent/HK1116161A1/xx not_active IP Right Cessation
-
2010
- 2010-11-12 US US12/945,575 patent/US8088794B2/en active Active
-
2011
- 2011-11-30 US US13/308,310 patent/US8685983B2/en active Active
-
2012
- 2012-11-26 CY CY20121101137T patent/CY1113324T1/el unknown
- 2012-12-27 HR HRP20121069TT patent/HRP20121069T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200708775B (en) | Substituted amide derivatives as protein kinase inhibitors | |
AU2009246263B2 (en) | Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer | |
CA2984259C (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
EP2139484B9 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
Schenone et al. | Antiangiogenic agents: an update on small molecule VEGFR inhibitors | |
Liang et al. | VEGF signal system: the application of antiangiogenesis | |
CN105120869A (zh) | 眼部病症的治疗 | |
JP2011512395A (ja) | 組合せ療法238 | |
MX2013007278A (es) | Compuestos de quinolina sustituidos y metodos de uso. | |
EA019506B1 (ru) | Конденсированные гетероциклические производные и их применение | |
EP1556051A2 (en) | Synergistic methods and compositions for treating cancer | |
JP2011520908A5 (es) | ||
JP2016530274A5 (es) | ||
AU2013296897A1 (en) | Substituted pyrazolone compounds and methods of use | |
ZA200106340B (en) | Quinazoline derivatives as angiogenesis inhibitors. | |
KR20230028484A (ko) | 암의 치료를 위한 병용 요법 | |
EP3274344A1 (en) | Formylated n-heterocyclic derivatives as fgfr4 inhibitors | |
Lyons III et al. | The role of VEGF pathways in human physiologic and pathologic angiogenesis | |
AU2013263043A1 (en) | Dosage regimen for a PI-3 kinase inhibitor | |
TW201529071A (zh) | 癌症治療組合療法 | |
JP2006525304A (ja) | Src阻害剤と組み合わせた抗血管新生剤を含む治療剤、およびその治療用用途 | |
JP2017141278A (ja) | Hsp90阻害剤とherceptin阻害剤との組合せ | |
CN103319468B (zh) | 取代的螺双环化合物及其使用方法和用途 | |
Wang et al. | Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis | |
CN113543784A (zh) | 用于治疗或预防癌症的喹啉衍生物 |